Asset
SPR-741
Spero Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03022175 | phase1 | completed | 2016-12-01 | 2017-07-01 | Spero Therapeutics | A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Healthy Volunteers |
| NCT03376529 | phase1 | completed | 2017-11-10 | 2017-12-19 | Spero Therapeutics | Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741 |
FDA applications (0)
This company has no applications containing this asset.